The Myeloid-Specific Transcription Factor PU.1 Upregulates Mannose Receptor Expression but Represses Basal Activity of the HIV-LTR Promoter
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
HIV-1 replication in primary human cells depends on the activity of virus-encoded proteins but also involves cellular factors that can either promote (viral dependency factors) or inhibit (host restriction factors) virus replication. In previous work, we identified human MRC1 as a macrophage-specific host restriction factor that inhibits the detachment of viral particles from infected cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The data here confirm findings from other groups that PU.1 regulates MRC1 expression44,53”
From HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages (2024) · cites this paper as [53]
Citations
Cites
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., & Martin, M. A. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,834
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130 · cited 1×
“1 is a member of the Ets family of transcription factors and is expressed exclusively in cells of the hematopoietic lineage (18).”
BackgroundVan Damme, N., Goff, D., Katsura, C., Jorgenson, R. L., Mitchell, R., Johnson, M. C., Stephens, E. B., & Guatelli, J. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.03.001 · Cited by 1,050
The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene
Klemsz, M. J., McKercher, S. R., Celada, A., Van Beveren, C., & Maki, R. A. (1990) · Cell · doi:10.1016/0092-8674(90)90219-5 · Cited by 954
Willey, R. L., Smith, D. H., Lasky, L. A., Theodore, T. S., Earl, P. L., Moss, B., Capon, D. J., & Martin, M. A. (1988) · Journal of Virology · doi:10.1128/jvi.62.1.139-147.1988 · Cited by 751
The HIV A (sor) gene product is essential for virus infectivity
Strebel, K., Daugherty, D., Clouse, K., Cohen, D., Folks, T., & Martin, M. A. (1987) · Nature · doi:10.1038/328728a0 · Cited by 479
Self-citationSpi-1 is a putative oncogene in virally induced murine erythroleukaemias
Moreau-Gachelin, F., Tavitian, A., & Tambourin, P. (1988) · Nature · doi:10.1038/331277a0 · Cited by 447 · cited 1×
“a putative oncogene encoded by the Spi-1 locus, which was associated with virally induced murine erythroleukemia (20).”
BackgroundZhang, D.-E., Hetherington, C. J., Chen, H.-M., & Tenen, D. G. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.373-381.1994 · Cited by 411
Species-Specific Activity of SIV Nef and HIV-1 Vpu in Overcoming Restriction by Tetherin/BST2
Jia, B., Serra-Moreno, R., Neidermyer, W., Rahmberg, A., Mackey, J., Fofana, I. B., Johnson, W. E., Westmoreland, S., & Evans, D. T. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000429 · Cited by 406
Igarashi, T., Brown, C. R., Endo, Y., Buckler-White, A., Plishka, R., Bischofberger, N., Hirsch, V., & Martin, M. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.658 · Cited by 361
Nef Proteins from Simian Immunodeficiency Viruses Are Tetherin Antagonists
Zhang, F., Wilson, S. J., Landford, W. C., Virgen, B., Gregory, D., Johnson, M. C., Munch, J., Kirchhoff, F., Bieniasz, P. D., & Hatziioannou, T. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2009.05.008 · Cited by 355
The CD16+ Monocyte Subset Is More Permissive to Infection and Preferentially Harbors HIV-1 In Vivo
Ellery, P. J., Tippett, E., Chiu, Y.-L., Paukovics, G., Cameron, P. U., Solomon, A., Lewin, S. R., Gorry, P. R., Jaworowski, A., Greene, W. C., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6581 · Cited by 348
A new pattern for helix–turn–helix recognition revealed by the PU.l ETS–domain–DNA complex
Kodandapani, R., Pio, F., Ni, C.-Z., Piccialli, G., Klemsz, M., McKercher, S., Maki, R. A., & Ely, K. R. (1996) · Nature · doi:10.1038/380456a0 · Cited by 315
Macrophages and their relevance in Human Immunodeficiency Virus Type I infection
Koppensteiner, H., Brack-Werner, R., & Schindler, M. (2012) · Retrovirology · doi:10.1186/1742-4690-9-82 · Cited by 280
Le Tortorec, A., & Neil, S. J. D. (2009) · Journal of Virology · doi:10.1128/jvi.01515-09 · Cited by 280
Neil, S. J. D., Sandrin, V., Sundquist, W. I., & Bieniasz, P. D. (2007) · Cell Host & Microbe · doi:10.1016/j.chom.2007.08.001 · Cited by 275
Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation
Pongubala, J., Van Beveren, C., Nagulapalli, S., Klemsz, M., McKercher, Maki, R., & Atchison, M. (1993) · Science · doi:10.1126/science.8456286 · Cited by 271 · cited 4×
“In particular, the interaction of PU.1 with another B cell-restricted nuclear factor, EM5, was shown to be dependent on PU.1 phosphorylation at Ser148 (24).”
BackgroundInfluentialRepression of MHC Class I Gene Promoter Activity by Two-Exon Tat of HIV
Howcroft, T. K., Strebel, K., Martin, M. A., & Singer, D. S. (1993) · Science · doi:10.1126/science.8493575 · Cited by 223
Self-citationTaking a new TAK on Tat transactivation
Jones, K. A. (1997) · Genes & Development · doi:10.1101/gad.11.20.2593 · Cited by 203
HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment
Hauser, H., Lopez, L. A., Yang, S. J., Oldenburg, J. E., Exline, C. M., Guatelli, J. C., & Cannon, P. M. (2010) · Retrovirology · doi:10.1186/1742-4690-7-51 · Cited by 163
Gupta, R. K., Mlcochova, P., Pelchen-Matthews, A., Petit, S. J., Mattiuzzo, G., Pillay, D., Takeuchi, Y., Marsh, M., & Towers, G. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907075106 · Cited by 160
Fisher, R. C., & Scott, E. W. (1998) · STEM CELLS · doi:10.1002/stem.160025 · Cited by 158
The transcription factor PU.1 is involved in macrophage proliferation.
Celada, A., Borràs, F. E., Soler, C., Lloberas, J., Klemsz, M., van Beveren, C., McKercher, S., & Maki, R. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.1.61 · Cited by 152 · cited 1×
“specific transcription factor that is involved in macrophage proliferation (33) and also”
BackgroundTat is a multifunctional viral protein that modulates cellular gene expression and functions
Clark, E. A., Nava, B. C., & Caputi, M. (2017) · Oncotarget · doi:10.18632/oncotarget.15174 · Cited by 149
Theodore, T. S., Englund, G., Buckler-White, A. J., Buckler, C. E., MARTIN, M. A., & Peden, K. (1996) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1996.12.191 · Cited by 146
Human cellular restriction factors that target HIV-1 replication
Strebel, K., Luban, J., & Jeang, K.-T. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-48 · Cited by 141
Self-citationWeissman, J. D., Brown, J. A., Howcroft, T. K., Hwang, J., Chawla, A., Roche, P. A., Schiltz, L., Nakatani, Y., & Singer, D. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11601 · Cited by 137
Hosokawa, H., Ungerbäck, J., Wang, X., Matsumoto, M., Nakayama, K. I., Cohen, S. M., Tanaka, T., & Rothenberg, E. V. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.024 · Cited by 116
Schubert, U., Clouse, K. A., & Strebel, K. (1995) · Journal of Virology · doi:10.1128/jvi.69.12.7699-7711.1995 · Cited by 107
Self-citationRay-Gallet, D., Mao, C. D., Tavitian, A., & Moreau-Gachelin, F. (1995) · PubMed · Cited by 105
The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies
Rice, A. P. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170704130635 · Cited by 105
Retraction Notice:Pathogenesis of Macrophage Tropic HIV-1
Gorry, P. R., Churchill, M. J., Crowe, S. M., Cunningham, A. L., & Gabuzda, D. H. (2005) · Current HIV Research · doi:10.2174/1570162052772951 · Cited by 102
Rice, A. P., & Carlotti, F. (1990) · Journal of Virology · doi:10.1128/jvi.64.4.1864-1868.1990 · Cited by 99
The Transcription Factor PU.1 is a Critical Regulator of Cellular Communication in the Immune System
Turkistany, S. A., & DeKoter, R. P. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0147-9 · Cited by 96
The RUNX1–PU.1 axis in the control of hematopoiesis
Imperato, M. R., Cauchy, P., Obier, N., & Bonifer, C. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1762-8 · Cited by 94
Activation of Transcription by PU.1 Requires both Acidic and Glutamine Domains
Klemsz, M. J., & Maki, R. A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.1.390 · Cited by 93
Reeder, J. E., Kwak, Y.-T., McNamara, R. P., Forst, C. V., & D’Orso, I. (2015) · eLife · doi:10.7554/elife.08955 · Cited by 85
Anti-tetherin activities in Vpu-expressing primate lentiviruses
Yang, S. J., Lopez, L. A., Hauser, H., Exline, C. M., Haworth, K. G., & Cannon, P. M. (2010) · Retrovirology · doi:10.1186/1742-4690-7-13 · Cited by 73
HIV-1 Tat Represses Transcription from the Mannose Receptor Promoter
Caldwell, R. L., Egan, B. S., & Shepherd, V. L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7035 · Cited by 54
HIV-1 Nef mediates post-translational down-regulation and redistribution of the mannose receptor
Vigerust, D. J., Egan, B. S., & Shepherd, V. L. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0804454 · Cited by 45
PU.1 drives specification of pluripotent stem cell-derived endothelial cells to LSEC-like cells
Smedt, J. D., van Os, E. A., Talón, I., Ghosh, S., Toprakhisar, B., da Costa, R. M., Zaunz, S., Vázquez, M. A., Boon, R., Baatsen, P., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03356-2 · Cited by 44
The Lipophilic Muramyl Peptide MTP-PE Is a Potent Inhibitor of HIV Replication in Macrophages
Lazdins, J. K., Woods-Cook, K., Walker, M. R., et al. (1990) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1990.6.1157 · Cited by 42
Lodie, T. A., Reiner, M., Coniglio, S., Viglianti, G., & Fenton, M. J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.1.268 · Cited by 42 · cited 1×
“1 on the HIV-1 LTR as opposed to the inhibitory effect reported here (44).”
BackgroundLodie, T. A., Reiner, M., Coniglio, S. J., Viglianti, G. A., & Fenton, M. J. (1998) · PubMed · Cited by 39
Mannose Receptor 1 Restricts HIV Particle Release from Infected Macrophages
Sukegawa, S., Miyagi, E., Bouamr, F., Farkašová, H., & Strebel, K. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.085 · Cited by 38
Self-citationThe HIV-1 Tat Protein Enhances Splicing at the Major Splice Donor Site
Mueller, N., Pasternak, A. O., Klaver, B., Cornelissen, M. T. E., Berkhout, B., & Das, A. T. (2018) · Journal of Virology · doi:10.1128/jvi.01855-17 · Cited by 35
Mannose receptor is an HIV restriction factor counteracted by Vpr in macrophages
Lubow, J., Virgilio, M. C., Merlino, M., Collins, D. R., Mashiba, M., Peterson, B. G., Lukic, Z., Painter, M. M., Gomez-Rivera, F., Terry, V., et al. (2020) · eLife · doi:10.7554/elife.51035 · Cited by 35
Tat, Tat-Associated Kinase, and Transcription
Jeang, K.-T. (1998) · Journal of Biomedical Science · doi:10.1007/bf02253352 · Cited by 31
Characterization of functional mannose receptor in a continuous hybridoma cell line
Vigerust, D. J., Vick, S., & Shepherd, V. L. (2012) · BMC Immunology · doi:10.1186/1471-2172-13-51 · Cited by 30
Gross, S. A., Zheng, J. H., Le, A. T., Kerzic, P. J., & Irons, R. (2006) · Cell Biology and Toxicology · doi:10.1007/s10565-006-0128-7 · Cited by 19
Chen, C., Shingai, M., Welbourn, S., Martin, M. A., Borrego, P., Taveira, N., & Strebel, K. (2016) · Journal of Virology · doi:10.1128/jvi.01451-16 · Cited by 18
Self-citationSites of Action of HIV-1 Vpu in BST-2/Tetherin Downregulation
Arias, J. F., Iwabu, Y., & Tokunaga, K. (2012) · Current HIV Research · doi:10.2174/157016212800792423 · Cited by 15
Zhao, M. L., Duan, X.-F., Wen, D., & Chen, G. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.03.024 · Cited by 15
Rouleux‐Bonnin, F., Monsigny, M. L. P., & Legrand, A. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1239 · Cited by 11
Cited by
HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages
Virgilio, M. C., Ramnani, B., Chen, T., Disbennett, W. M., Lubow, J., Welch, J. D., & Collins, K. L. (2024) · Nature Communications · doi:10.1038/s41467-024-49635-w · Cited by 14
“Prior reports indicated that PU.1 suppresses HIV gene expression in a Tat-reversible manner 53 .”
Metadata
- Authors
- Kao, S., Miyagi, E., Mallorson, R., Saito, H., Sukegawa, S., Mukherji, A., Mateja, A., Ferhadian, D., Fabryova, H., Clouse, K., & Strebel, K.
- Affiliations
- National Institutes of Health (US)
- Tokyo Medical and Dental University (JP)
- Frederick National Laboratory for Cancer Research (US)
- Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA
- United States Food and Drug Administration (US)
- Corresponding author
- Strebel, Klaus
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2022-07-27
- Volume
- 96
- Issue
- 14
- Pages
- e0065222-e0065222
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC9327697
- OpenAlex
- W4283717576
- Cited by
- 8
- References
- 54
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 1
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- doi.org/10.1128/AuthorWarrantyLicense.v1 (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (1 Z01 AI000669, 75N91019D00024)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- PU.1, CD206, HIV-1, host restriction factors, Tat, transcriptional repression, macrophages
- MeSH terms
- Mannose Receptor, Proto-Oncogene Protein Spi-1, Humans, Macrophages, Promoter Regions, Genetic, HIV-1, Transcriptional Activation, HIV Infections, Up-Regulation, Gene Expression Regulation, Viral, HIV Long Terminal Repeat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.